Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 212

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 6
Chunk 212
---
 expect that the
aggregate base compensation payable by us and our subsidiaries to our executive officers and directors as a group will be in the aggregate
amount of approximately $2.4 million. This amount excludes potential salary raises, bonuses and share-based compensation, which have not
yet been determined for 2025.

The following is a summary
of the salary expenses and social benefit costs of our five most highly compensated executive officers in 2024, or the “ Covered
Executives.” All amounts reported reflect the cost to the Company as recognized in our financial statements for the year ended December
31, 2024. U. S. dollar amounts indicated for compensation of our Covered Executives are in thousands of dollars.

  Mr. Uzi Sofer, Chief Executive                                                                                                   

  Dr. Robert Den, Chief Medical                                                                                 

  Mr. Raphi Levy, Chief Financial                                                                               

  Mr. Amnon Gat, Chief Operating                                                                                

  Mr. Ronen Segal, Chief Technology                                                                             

The salary expenses summarized
above include the gross salary paid to the Covered Executives, and the benefit costs include the social benefits paid by us on behalf
of the Covered Executives, Company car expenses, convalescence pay, contributions made by the company to an insurance policy or a pension
fund, work disability insurance, severance, educational fund and payments for social security.

In accordance with the Company’s
compensation policy, we also paid cash bonuses or commissions to our Covered Executives upon compliance with predetermined performance
parameters and an over achievement bonus as set by the compensation committee and the board of directors. The 2024 cash bonus or commissions
expenses for Mr. Sofer, Dr. Den, Mr. Levy, Mr. Gat and Mr. Segal, as provided for in our 2024 financial statements, were $445, $222, $243,
$220 and $110, respectively.

We recorded equity-based compensation
expenses in our financial statements for the year ended December 31, 2024 for Mr. Sofer, Dr. Den, Mr. Levy, Mr. Gat and Mr. Segal, as
provided for in our 2024 financial statements, were $2.16 million, $1.21 million, $988, $736 and $571, respectively.

All equity-based compensation
grants to our Covered Executives were made in accordance with the parameters of our Company’s compensation policy and were approved
by the Company’s compensation committee and board of